September 1, 2015
The Department of Chemistry is delighted to announce that Allied-Bristol Life Sciences (ABLS) has licensed a proprietary platform technology developed in the laboratory of Professor David Spiegel. The Spiegel immuno-oncology platform and associated lead molecules-known as Antibody-Recruiting molecules (ARMs)-provide a novel approach to the treatment of various forms of cancer. For more information click here.